1-8 of 8
Susan Sheng, PhD
Close
Sort by
Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-141495
Published: 2020
Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141409
Published: 2020
Journal Articles

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Hongying Zhang, MD, PhD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Taryn McLaughlin, MS, Alexey V Danilov, MD PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Stephen Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3503.
https://doi.org/10.1182/blood-2018-99-117285
Published: 2018
Journal Articles

Synthetic Lethal Interaction between Apto-253 and Impaired BRCA1/2 Function

Cheng-Yu Tsai, PhD, Si Sun, MD, Hongying Zhang, MD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, William Rice, PhD, Stephen Howell, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5000.
https://doi.org/10.1182/blood.V130.Suppl_1.5000.5000
Published: 2017
Journal Articles

APTO-253 Interaction with G-Quadruplex DNA Is Linked to Inhibition of c-Myc Expression, Induction of DNA Damage, and Generation of Synthetic Lethality in Cells with BRCA1/2 Impairment

Andrea Local, PhD, Hongying Zhang, MD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Cheng-Yu Tsai, PhD, Stephen Howell, MD, William Rice, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5094.
https://doi.org/10.1182/blood.V130.Suppl_1.5094.5094
Published: 2017
Journal Articles

CG '806, a Highly Potent First-in-Class Pan-FLT3/BTK Inhibitor, Targets Multiple Clusters of Kinases Operative in Diverse Subtypes of Acute Myeloid Leukemia

Hongying Zhang, MD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Cheng-Yu Tsai, PhD, Stephen Howell, MD, William Rice, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5063.
https://doi.org/10.1182/blood.V130.Suppl_1.5063.5063
Published: 2017
Journal Articles

CG '806, a First-in-Class Non-Covalent Pan-FLT3/BTK Inhibitor, Exerts Superior Potency Against B-Cell Malignant Cells

Hongying Zhang, MD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Cheng-Yu Tsai, PhD, Stephen Howell, MD, William Rice, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5200.
https://doi.org/10.1182/blood.V130.Suppl_1.5200.5200
Published: 2017
Journal Articles

Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Hongying Zhang, MD PhD, Andrea Local, PhD, Khalid Benbatoul, Peter Folger, Susan Sheng, PhD, Luis Esquivies, PhD, Jeff Lightfoot, PhD, Avanish Vellanki, William G. Rice, PhD
Journal: Blood
Blood (2016) 128 (22): 1716.
https://doi.org/10.1182/blood.V128.22.1716.1716
Published: 2016